Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
December 18, 2023 09:39 ET
|
Immix Biopharma, Inc.
Dr. Radic led and authored landmark study demonstrating applicability of CAR-Ts in autoimmune diseases published in Science Translational Medicine, 2019 Dr. Radic is a recognized...
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
December 11, 2023 09:36 ET
|
Immix Biopharma, Inc.
100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6...
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
November 30, 2023 09:46 ET
|
Immix Biopharma, Inc.
LOS ANGELES, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage biopharmaceutical company pioneering personalized therapies...
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
November 22, 2023 09:19 ET
|
Immix Biopharma, Inc.
LOS ANGELES, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies...
Immix Biopharma gibt die FDA-Genehmigung des IND-Antrags für CAR-T NXC-201 bekannt, der die Verabreichung an US-Patienten ermöglicht
November 22, 2023 03:20 ET
|
Immix Biopharma, Inc.
NEXICART-2 weitet Studien mit NXC-201 bei rezidivierter/refraktärer AL-Amyloidose nach IND-Freigabe auf Prüfzentren in den USA aus 72 Patienten außerhalb der USA, die zuvor mit NXC-201 behandelt...
La FDA approuve le dossier d’essai clinique de Immix Biopharma CAR-T NXC-201, et en permet ainsi l’administration aux patients américains
November 22, 2023 03:20 ET
|
Immix Biopharma, Inc.
À la suite de l’autorisation de la FDA, NEXICART-2 va poursuivre les essais sur le NXC-201 dans le traitement de l’amylose AL en rechute ou réfractaire sur les sites américains 72 patients ont déjà...
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
November 21, 2023 09:46 ET
|
Immix Biopharma, Inc.
NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance72 patients previously dosed with NXC-201 ex-U.S.First CAR-T program for light-chain...
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
November 21, 2023 09:46 ET
|
Immix Biopharma, Inc.
NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance72 patients previously dosed with NXC-201 ex-U.S.First CAR-T program for light-chain...
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients
November 06, 2023 09:12 ET
|
Immix Biopharma, Inc.
100% overall response rate observed in relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapyUpdated results will be communicated at the presentation time December 10,...
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients
November 06, 2023 08:40 ET
|
Immix Biopharma, Inc.
95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy98% overall response rate observed in relapsed/refractory...